KR102890748B1 - 바이러스 안정화제, 바이러스 안정화제용 젤라틴 가수분해물 및 바이러스 함유 조성물 - Google Patents

바이러스 안정화제, 바이러스 안정화제용 젤라틴 가수분해물 및 바이러스 함유 조성물

Info

Publication number
KR102890748B1
KR102890748B1 KR1020227044891A KR20227044891A KR102890748B1 KR 102890748 B1 KR102890748 B1 KR 102890748B1 KR 1020227044891 A KR1020227044891 A KR 1020227044891A KR 20227044891 A KR20227044891 A KR 20227044891A KR 102890748 B1 KR102890748 B1 KR 102890748B1
Authority
KR
South Korea
Prior art keywords
virus
gelatin
stabilizer
days
containing composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227044891A
Other languages
English (en)
Korean (ko)
Other versions
KR20230014737A (ko
Inventor
가쓰로 하기와라
마사타카 이다
요스케 히라오카
프랑소와 마리 응가코 카지
가즈키 고타니
히로시 쓰카모토
Original Assignee
니타 젤라틴 가부시키가이샤
각코우호우진 라쿠노 가쿠엔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니타 젤라틴 가부시키가이샤, 각코우호우진 라쿠노 가쿠엔 filed Critical 니타 젤라틴 가부시키가이샤
Publication of KR20230014737A publication Critical patent/KR20230014737A/ko
Application granted granted Critical
Publication of KR102890748B1 publication Critical patent/KR102890748B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18621—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227044891A 2021-01-19 2021-11-16 바이러스 안정화제, 바이러스 안정화제용 젤라틴 가수분해물 및 바이러스 함유 조성물 Active KR102890748B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-006669 2021-01-19
JP2021006669 2021-01-19
PCT/JP2021/042018 WO2022158097A1 (ja) 2021-01-19 2021-11-16 ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物

Publications (2)

Publication Number Publication Date
KR20230014737A KR20230014737A (ko) 2023-01-30
KR102890748B1 true KR102890748B1 (ko) 2025-11-26

Family

ID=82548688

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044891A Active KR102890748B1 (ko) 2021-01-19 2021-11-16 바이러스 안정화제, 바이러스 안정화제용 젤라틴 가수분해물 및 바이러스 함유 조성물

Country Status (7)

Country Link
US (1) US20230183657A1 (https=)
EP (1) EP4282955A4 (https=)
JP (1) JP7837512B2 (https=)
KR (1) KR102890748B1 (https=)
CN (1) CN115836123B (https=)
CA (1) CA3174826A1 (https=)
WO (1) WO2022158097A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117070476B (zh) * 2023-10-13 2023-12-19 金宇保灵生物药品有限公司 一株牛疱疹病毒4型毒株及其在灭活疫苗制备中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011739A1 (en) * 2003-08-05 2005-02-10 Fuji Photo Film B.V. Use of recombinant or synthetic gelatin as a stabiliser in vaccines
WO2020049151A1 (en) * 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54140715A (en) * 1978-01-16 1979-11-01 Merck & Co Inc Vaccine stabilizer
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
CN1073858C (zh) * 1998-10-28 2001-10-31 浙江普康生物技术股份有限公司 含有稳定剂的甲型肝炎减毒活疫苗及制备方法
KR100294375B1 (ko) * 1998-12-29 2001-09-17 정지석 수두생바이러스백신용안정화제
JP4401226B2 (ja) 2004-04-16 2010-01-20 ミドリホクヨー株式会社 コラーゲン化粧料、その製造方法、可溶化コラーゲン繊維及びその製造装置
EP2769735B1 (en) 2004-10-06 2017-04-19 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions
AP2015008733A0 (en) * 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
ES2948037T3 (es) * 2014-12-18 2023-08-30 Amgen Inc Formulación estable congelada del virus del herpes simple
WO2017041083A1 (en) * 2015-09-04 2017-03-09 Inventprise, Llc Vlp stabilized vaccine compositions
WO2017056101A1 (en) * 2015-09-30 2017-04-06 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
US20190275136A1 (en) 2016-09-19 2019-09-12 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US10815456B2 (en) * 2016-10-04 2020-10-27 Transwell Biotech Co., Ltd. Composition, kit and method for cryopreserving cells
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
JPWO2021020446A1 (https=) * 2019-07-30 2021-02-04

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011739A1 (en) * 2003-08-05 2005-02-10 Fuji Photo Film B.V. Use of recombinant or synthetic gelatin as a stabiliser in vaccines
WO2020049151A1 (en) * 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Immune Based Therapies and Vaccines, 2007, 5:4.*

Also Published As

Publication number Publication date
CN115836123B (zh) 2024-12-31
WO2022158097A1 (ja) 2022-07-28
KR20230014737A (ko) 2023-01-30
CN115836123A (zh) 2023-03-21
EP4282955A1 (en) 2023-11-29
JPWO2022158097A1 (https=) 2022-07-28
JP7837512B2 (ja) 2026-03-31
US20230183657A1 (en) 2023-06-15
EP4282955A4 (en) 2025-01-15
CA3174826A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
ES2299275T3 (es) Procedimiento y composiciones para conservar adenovirus.
ES2386457T3 (es) Composición de estabilizador químicamente definida
CN103041383B (zh) 一种活疫苗的耐热冻干保护剂、活疫苗冻干粉及其制备方法
US20100015177A1 (en) Method for Preserving Viral Particles
EP2968112B2 (en) Stable aqueous formulations of adenovirus vectors
JP2005515245A (ja) アデノウィルスの安定化された配合物
CN106729731A (zh) 一种疫苗耐热保护剂、疫苗以及疫苗的制备方法
CN103041399A (zh) 一种耐热保护剂及其应用
KR102890748B1 (ko) 바이러스 안정화제, 바이러스 안정화제용 젤라틴 가수분해물 및 바이러스 함유 조성물
CN101052714B (zh) 稳定性和滤过性有包膜病毒制剂
WO2023023371A1 (en) Formulations containing amino acids for stabilizing lipid enveloped viral and non-viral vectors
EP1651275A1 (en) Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions
JP4332694B2 (ja) 水溶性乾燥組成物
EP3127550A1 (en) Stabilizing composition for dry formulation of virus
Saengkrit et al. Dry formulations enhanced mucoadhesive properties and reduced cold chain handing of influenza vaccines
JP4253688B2 (ja) 凍結乾燥用保護剤及び生理活性物質の製造方法
Kadji et al. Stability of Enveloped and Nonenveloped Viruses in a Stable Gelatin Liquid Formulation
US20240382541A1 (en) Formulations to stabilize virus-based therapeutics
KR20260012760A (ko) 바이러스-기반 치료제를 안정화시키는 제형
CN119548638A (zh) 一种活疫苗耐热保护剂及其制备方法和应用
CN108619521A (zh) 一种动物非灭活疫苗冷冻干燥保护剂及其使用方法
BR112020021358A2 (pt) Métodos de proteção da atividade biológica de uma molécula biologicamente ativa, de uma pluralidade de moléculas de uma molécula biologicamente ativa, e, da atividade biológica de uma proteína biologicamente ativa
NZ554550A (en) Stable and filterable enveloped virus formulations

Legal Events

Date Code Title Description
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)